D. Ferry

Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition.

D. Ferry, Adam J. de Smith, J Malkhandi et al. · PubMed · 1996 · 630 citations

Medicine, Pharmacokinetics, Pharmacology +12

Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life

M.H. Cullen, Lucinda Billingham, C.M. Woodroffe et al. · Journal of Clinical Oncology · 1999 · 449 citations

Medicine, Oncology, Pharmacology +12

Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

Sarah Danson, D. Ferry, Valery Yu. Alakhov et al. · British Journal of Cancer · 2004 · 377 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification

Eric Van Cutsem, Yu Jeong Bang, Wasat Mansoor et al. · Annals of Oncology · 2017 · 187 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin

Paul Mulholland, D. Ferry, David Anderson et al. · Annals of Oncology · 2001 · 159 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +4